The molecular classification of adenocarcinoma subgroup is established and is well known, where the most frequent genetic alteration among non-Asian patients is KRAS mutation (1/3) followed by EGFR (5%–15%) while in Asian patients EGFR mutation is the most frequent followed by KRAS mutation [1, 2]. This evidence concerns the gene EGFR and adenocarcinoma.